IFNG and neoplasm: However, many patients are resistant to immune checkpoint inhibitors, and the mechanisms include the lack of suitable tumor antigens, dysfunction of Major Histocompatibility Complex on the surface of tumors, abnormal IFN-γ signaling pathway, and immunosuppressive tumor microenvironment [18].